Seven Bridges Is Named to MIT Technology Review’s Annual 50 Smartest Companies List

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seven
Bridges, the biomedical data analysis company, has been named to MIT
Technology Review’s 2016 list of 50 Smartest Companies. To make the
list, a company must have innovative technology and a business model
that is both practical and ambitious, with the result that it has set
the agenda in its field over the past 12 months.
Jason Pontin, publisher and editor in chief, states, “Each year we
identify 50 companies that are ‘smart’ in the way they create new
opportunities. Some of this year’s stars are large companies that are
using digital technologies to redefine industries, while others wrestle
with technological changes. Also on the list are ambitious startups
looking to make their mark in an existing marketplace or create a new
market entirely.”
“We are honored to be included and recognized for our role in driving
precision medicine initiatives forward,” said James Sietstra, President,
Seven Bridges. “Our technology helps enable scalable and collaborative
biomedical data analysis. We are excited to help researchers around the
world collaborate on their work and learn from vast quantities of
genomic data.”
The list is included in MIT Technology Review’s annual business issue,
which is available online now at www.technologyreview.com
and on newsstands worldwide on July 5, 2016.
About MIT Technology Review
Founded at MIT in 1899, MIT Technology Review is an independent media
company whose mission is to explain the commercial, social, and
political impact of new technologies. Readers are a global audience of
business and thought leaders, innovators and early adopters,
entrepreneurs and investors. We’re first to report on a broad range of
new technologies, informing our audiences about how important
breakthroughs will impact their careers and lives. Subscribe. Follow:
Twitter, Facebook, LinkedIn, Google+.
About Seven Bridges
Seven Bridges is the biomedical data analysis company accelerating
breakthroughs in genomics research for cancer, drug development and
precision medicine. The scalable, cloud-based Seven
Bridges Platform empowers rapid, collaborative analysis of millions
of genomes in concert with other forms of biomedical data. Thousands of
researchers in government, biotech, pharmaceutical and academic labs use
Seven Bridges, including three of the largest genomics projects in the
world: U.S. National Cancer Institute’s Cancer
Genomics Cloud pilot, the Million
Veteran Program and Genomics England’s 100,000
Genomes Project. As the NIH’s only commercial Trusted
Partner, Seven Bridges authenticates and authorizes access to one of
the world’s largest cancer genomics dataset. The company has offices in
Cambridge, Mass.; Belgrade; London and San Francisco.